EUCTR2019-003426-24-IT进行中（未招募）1 期
24-hour efficacy and tolerability of the tafluprost-timolol fixed association without preservatives in glaucomatous or ocular hypertensive patients already treated with latanoprost preserved with BAK. A Prospective, open study of 3 months duration. - HERO
IRCCS FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA ONLUS0 个研究点目标入组 43 人开始时间: 2020年7月30日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Ocular hypertension or primary open-angle glaucoma or secondary to dispersion of pigment or pseudoesfoliatio;
- •2.IOP <22 mmHg in latanoprost therapy in both eyes and> 17 mmHg in at least one eye;
- •3.OSD at least mild as defined by DEQ-5 (score> 6);
- •4.Examination of the visual field during the three months prior to enrollment (if not present, the patient must be subjected to a visual field at the screening visit);
- •5.Treatment with latanoprost BAK-preserved from at least 6 weeks;
- •6.Subject agrees to follow the study procedures and signs the EC-approved ICF;
- •7.For women of child-bearing potential, blood screening for beta-HCG before randomization and use of one effective method of birth control during the conduct of the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 22
排除标准
- •1.Inability to understand and sign informed consent;
- •2.Age under 18 years;
- •3.Other forms of secondary glaucoma (besides pigmentary and pseudoesfoliatius);
- •4.Narrow angle or history of acute glaucoma attacks;
- •5.Previous history of trabeculoplasty in the previous 6 months;
- •6.History of glaucoma surgery or refractive surgery;
- •7.Cataract surgery in the 6 months prior to enrollment;
- •8.Contraindications to the use of beta-blockers (reactive airway disease, including bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease; sinus bradycardia, sick sinus syndrome, including sinoatrial block, second or third degree atrioventricular block not controlled by pacemaker; full-blown heart failure, cardiogenic shock);
- •9.Damage to the visual field with a mean deviation (MD) <-20 dB;
- •10.BCVA <2/10;
- •11.Topical ocular drugs performed within 3 months prior to enrollment that may interfere with the study results (eg steroids, non-steroidal anti-inflammatory drugs, immunosuppressants, etc.);
- •12.Use of tear substitutes containing preservatives within 30 days prior to enrollment;
- •13.Any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the patient or would preclude the patient from successful completion of the study or would impair interpretation of results;
- •14.Corneal anomalies that preclude an accurate measurement of IOP (eg astigmatism> 3 D, keratoconus, opacity or corneal ulcers);
- •15.Any type of previous corneal or conjunctival surgery including pterygium removal or refractive surgery;
- •16.Unstable systemic disorders that may require the initiation or variation of therapies that may influence intraocular pressure during the study;
- •17.Woman of childbearing potential, or who is currently pregnant or breastfeeding;
- •18.Inability to adhere to the procedures required by the protocol or to the studio treatment;
- •19.Participation in another experimental therapeutic protocol within one month prior to baseline and during the study period (participation in natural history study is allowed);
- •20.Hypersensitivity to the active substances or to any of the excipients.
研究者
相似试验
Unknown
4 期
24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.Glaucoma, Open-AngleOcular HypertensionNCT05299593Fondazione G.B. Bietti, IRCCS43
进行中（未招募）
不适用
Effectiveness after 4 and 24 weeks and safety of tocilizumab in patients with active RA - TAMARA - Tocilizumab And DMARDs: Achievements in Rheumatoid ArthritisMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2008-000105-11-DERoche Pharma AG
已完成
4 期
Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening DosingGlaucoma, Open-AngleNCT03612817Aristotle University Of Thessaloniki42
进行中（未招募）
1 期
Efficacy Study Of Tofacitinib In Pediatric JIA PopulatioJUVENILE IDIOPATHIC ARTHRITIS (JIA)MedDRA version: 20.0 Level: PT Classification code 10059176 Term: Juvenile idiopathic arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2015-001438-46-BEPfizer Inc, 235 East 42nd Street, New York, New York 10017210
进行中（未招募）
1 期
Efficacy Study Of Tofacitinib In Pediatric JIA PopulatioJUVENILE IDIOPATHIC ARTHRITIS (JIA)MedDRA version: 20.0 Level: PT Classification code 10059176 Term: Juvenile idiopathic arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2015-001438-46-ESPfizer Inc, 235 East 42nd Street, New York, New York 10017210